Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II 'FIRST' study

被引：0

作者：

Robertson, John F. R. ^{[1
]}

Llombart-Cussac, Antonio ^{[2
]}

Feltl, David ^{[3
]}

Dewar, John ^{[4
]}

Jasiowka, Marek ^{[5
]}

Hewson, Nicola ^{[6
]}

Rukazenkov, Yuri ^{[6
]}

Ellis, Matthew J. ^{[7
]}

机构：

[1] Univ Nottingham, Nottingham NG7 2RD, England

[2] Hosp Arnau Vilanova, Lleida, Spain

[3] Radioterapeut Klin, FNsP Ostrava, Ostrava, Czech Republic

[4] Ninewells Hosp & Med Sch, Dundee, Scotland

[5] Inst Marii Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland

[6] AstraZeneca, Bonifacio Global City, Taguig, Philippines

[7] Washington Univ, Sch Med, St Louis, MO 63130 USA

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS14-S6-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

S6-04

引用

页数：2